Pub Date : 2016-01-01DOI: 10.4172/2329-6771.1000175
A. Sultan, Hassan Kaleem, S. Radhi
Colorectal carcinoma is the third most common cancer diagnosed in females in the United States [1]. It accounts for 8% of the new cancers diagnosed in women and an estimated 63,700 new cases of CRC expected in 2015. CRC diagnosed in pregnancy is not common with an incidence of 1 in 13,000 pregnancies [2-4]. Management of a pregnant woman with CRC is challenging due to various unknowns to guide the antineoplastic treatment decision. CRC cases during pregnancy and use of chemotherapy agents have reported in the past decade [5-12]. Reporting of management of such situations is helpful in assisting clinicians to further investigating the use of chemotherapy agents in pregnancy. We report an unusual, but the challenging case of 24-year-old pregnant women diagnosed with metastatic colon cancer as a consequence of lunch syndrome treated with FOLFOX chemo regimen with no apparent fetal harm.
{"title":"Treatment of Metastatic Colorectal Cancer in a Pregnant Woman with Lynch Syndrome- A Case Report","authors":"A. Sultan, Hassan Kaleem, S. Radhi","doi":"10.4172/2329-6771.1000175","DOIUrl":"https://doi.org/10.4172/2329-6771.1000175","url":null,"abstract":"Colorectal carcinoma is the third most common cancer diagnosed in females in the United States [1]. It accounts for 8% of the new cancers diagnosed in women and an estimated 63,700 new cases of CRC expected in 2015. CRC diagnosed in pregnancy is not common with an incidence of 1 in 13,000 pregnancies [2-4]. Management of a pregnant woman with CRC is challenging due to various unknowns to guide the antineoplastic treatment decision. CRC cases during pregnancy and use of chemotherapy agents have reported in the past decade [5-12]. Reporting of management of such situations is helpful in assisting clinicians to further investigating the use of chemotherapy agents in pregnancy. We report an unusual, but the challenging case of 24-year-old pregnant women diagnosed with metastatic colon cancer as a consequence of lunch syndrome treated with FOLFOX chemo regimen with no apparent fetal harm.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"67 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91310107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.4172/2329-6771.1000170
C. Elm’hadi, Mohammed Reda Khmamouche, M. Toreis, R. Tanz, T. Mahfoud, H. Errihani, M. Ichou
Only a few cases of malignant peripheral nerve sheath tumor (MPNST) associated with Von Recklinghausen’s disease or type I neurofibromatosis (NF-1) have so far been reported worldwide. We present a case of a 27 year old man with MPNST of the left thigh associated with NF-1. The diagnosis was based on clinical, radiological and histopathological evidence. He presented a large mass of thigh, deeply adhering, with the presence of collateral venous circulation. He also presented multiple cafe-au-lait spots, with a many neurofibromas. MRI of the hip and left thigh showed the presence of a bulky tissue process, badly limited, measuring 24,6×11×12 cm occupying the anterolateral and posterolateral lodge with an intermediate signal in T1, discreetly more intense in T2. The microscopic and immunohistochemical findings supported the final diagnosis of MPNST with mesenchymal differentiation. The staging was negative. Also, the diagnosis of NF-1 is held according to the presence of two NIH criteria. The decision of the multidisciplinary meeting was to make a neoadjuvant chemotherapy to surgery with a doublet of adriamycin and ifosfamide with surveillance for other tumor development or multisystem complications. The presence of a large mass on the path of a peripheral nerve requires a careful examination of the skin for signs evoking a von Recklinghausen disease.
{"title":"A Huge Malignant Peripheral Nerve Sheath Tumor Revealing Von Recklinghausen's Disease","authors":"C. Elm’hadi, Mohammed Reda Khmamouche, M. Toreis, R. Tanz, T. Mahfoud, H. Errihani, M. Ichou","doi":"10.4172/2329-6771.1000170","DOIUrl":"https://doi.org/10.4172/2329-6771.1000170","url":null,"abstract":"Only a few cases of malignant peripheral nerve sheath tumor (MPNST) associated with Von Recklinghausen’s disease or type I neurofibromatosis (NF-1) have so far been reported worldwide. We present a case of a 27 year old man with MPNST of the left thigh associated with NF-1. The diagnosis was based on clinical, radiological and histopathological evidence. He presented a large mass of thigh, deeply adhering, with the presence of collateral venous circulation. He also presented multiple cafe-au-lait spots, with a many neurofibromas. MRI of the hip and left thigh showed the presence of a bulky tissue process, badly limited, measuring 24,6×11×12 cm occupying the anterolateral and posterolateral lodge with an intermediate signal in T1, discreetly more intense in T2. The microscopic and immunohistochemical findings supported the final diagnosis of MPNST with mesenchymal differentiation. The staging was negative. Also, the diagnosis of NF-1 is held according to the presence of two NIH criteria. The decision of the multidisciplinary meeting was to make a neoadjuvant chemotherapy to surgery with a doublet of adriamycin and ifosfamide with surveillance for other tumor development or multisystem complications. The presence of a large mass on the path of a peripheral nerve requires a careful examination of the skin for signs evoking a von Recklinghausen disease.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"38 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82716022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2016-01-01DOI: 10.4172/2329-6771.S1-001
H. Kitayama, T. Kondo
{"title":"Paraneoplastic Erythrocytosis of Colon Cancer within Normal Reference Range in Serum Erythropoietin Level","authors":"H. Kitayama, T. Kondo","doi":"10.4172/2329-6771.S1-001","DOIUrl":"https://doi.org/10.4172/2329-6771.S1-001","url":null,"abstract":"","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"173 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79866660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-26DOI: 10.4172/2329-6771.1000155
N. Kawata, T. Igarashi, Kenya Yamaguchi, H. Hirakata, Satoru Takahashi
We experienced a case of renal cell carcinoma in congenital solitary kidney of an 80-year old male with a status post bypass grafts of coronary arteries and advanced heart failure. Incidentally we identified a left renal cell carcinoma 60mm in diameter, and an aneurysm of left renal artery. According to the R.E.N.A.L. Nephrometry Score, the tumor had 2-2-3-2 and total 9 points. Preoprerative e-GFR was 62.1 ml/min. He underwent open nephron sparing surgery by using intestinal forceps for kidney clamp instead of vascular clamp. Following an uneventful postoperative course, e-GFR became 45.6 ml/min. No recurrence was observed at 25 months after surgery. Even though laparoscopic partial nephrectomy is the gold standard for small renal mass, open procedure is still a mainstay for imperative cases.
{"title":"Kidney Clamp by Using Intestinal Forceps during Nephron SparingSurgery","authors":"N. Kawata, T. Igarashi, Kenya Yamaguchi, H. Hirakata, Satoru Takahashi","doi":"10.4172/2329-6771.1000155","DOIUrl":"https://doi.org/10.4172/2329-6771.1000155","url":null,"abstract":"We experienced a case of renal cell carcinoma in congenital solitary kidney of an 80-year old male with a status post bypass grafts of coronary arteries and advanced heart failure. Incidentally we identified a left renal cell carcinoma 60mm in diameter, and an aneurysm of left renal artery. According to the R.E.N.A.L. Nephrometry Score, the tumor had 2-2-3-2 and total 9 points. Preoprerative e-GFR was 62.1 ml/min. He underwent open nephron sparing surgery by using intestinal forceps for kidney clamp instead of vascular clamp. Following an uneventful postoperative course, e-GFR became 45.6 ml/min. No recurrence was observed at 25 months after surgery. Even though laparoscopic partial nephrectomy is the gold standard for small renal mass, open procedure is still a mainstay for imperative cases.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"39 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2015-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84357059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-13DOI: 10.4172/2329-6771.1000153
E. Choe, H. Kang
Background: The carcinoembryonic antigen (CEA) is widely used as a tumor marker because of its overexpression in adenocarcinomas, particularly colorectal cancer. The aim of this study was to investigate the metabolic factors including visceral obesity that are associated with serum CEA levels in non-smokers. Methods: This was a cross-sectional study of 1958 Koreans (1181 males, mean age 54.6 ± 8.7 years) who underwent serum CEA level and computed tomography-based visceral fat area assessments on the same day as a screening examination. The subjects were divided into 2 groups according to their median CEA level (1.20 ng/mL). Results: The multivariable analysis revealed that CEA was associated with age (OR=1.029, 95% CI=1.017 – 1.040, P<0.001), being male (OR=1.650, 95% CI=1.210 – 2.250, P=0.002) and glycosylated hemoglobin (HbA1c) values (OR=1.386, 95% CI=1.103 – 1.742, P=0.005) but not with visceral fat area after adjusting for age, gender and other variables. Among the diabetic patients, the mean CEA level was significantly higher in the group with HbA1c values ≥ 7.0% than in those with HbA1c values<7.0% (P=0.023). After adjusting for confounding factors, the association between CEA levels and poorly controlled diabetes (HbA1c ≥ 7.0%) persisted (OR=2.331, 95% CI=1.323 – 4.108, P=0.003). Conclusion: A serum CEA level within the normal range was related to the HbA1c level but not to visceral fat in Korean non-smokers, particularly among those with poorly controlled diabetes.
{"title":"The Serum Carcinoembryonic Antigen is Associated with HbA1c inKorean Non-Smokers","authors":"E. Choe, H. Kang","doi":"10.4172/2329-6771.1000153","DOIUrl":"https://doi.org/10.4172/2329-6771.1000153","url":null,"abstract":"Background: The carcinoembryonic antigen (CEA) is widely used as a tumor marker because of its overexpression in adenocarcinomas, particularly colorectal cancer. The aim of this study was to investigate the metabolic factors including visceral obesity that are associated with serum CEA levels in non-smokers. Methods: This was a cross-sectional study of 1958 Koreans (1181 males, mean age 54.6 ± 8.7 years) who underwent serum CEA level and computed tomography-based visceral fat area assessments on the same day as a screening examination. The subjects were divided into 2 groups according to their median CEA level (1.20 ng/mL). Results: The multivariable analysis revealed that CEA was associated with age (OR=1.029, 95% CI=1.017 – 1.040, P<0.001), being male (OR=1.650, 95% CI=1.210 – 2.250, P=0.002) and glycosylated hemoglobin (HbA1c) values (OR=1.386, 95% CI=1.103 – 1.742, P=0.005) but not with visceral fat area after adjusting for age, gender and other variables. Among the diabetic patients, the mean CEA level was significantly higher in the group with HbA1c values ≥ 7.0% than in those with HbA1c values<7.0% (P=0.023). After adjusting for confounding factors, the association between CEA levels and poorly controlled diabetes (HbA1c ≥ 7.0%) persisted (OR=2.331, 95% CI=1.323 – 4.108, P=0.003). Conclusion: A serum CEA level within the normal range was related to the HbA1c level but not to visceral fat in Korean non-smokers, particularly among those with poorly controlled diabetes.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"4 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2015-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79470260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-12-13DOI: 10.4172/2329-6771.1000154
Chong-mei Huang, Hui Cheng, Xiaoqian Xu, Xianmin Song, Li Chen, Jianmin Yang
The human epoxide hydrolase 1 (EPHX1) is a metabolism gene, which is responsible for the first phase of the xenobiotic metabolism. The product, microsomal epoxide hydrolase (mHE), plays an important role in the detoxification of carcinogenic polycyclic aromatic hydrocarbons. Many reports also have studied the correlation between EPHX1 gene polymorphisms and development and generation of cancers. However, few of studies on EPHX1 participating in chemotherapeutics metabolism were reported. The purpose of the present study was to evaluate the prognostic significance of the EPHX1gene expression in acute myeloid leukemia (AML). Using real timeâquantitative polymerase chain reaction (RTâqPCR), mRNA expression levels of EPHX1gene was measured in bone marrow samples of newly diagnosed AML patients (n=46) and control group (n=12) without tumors. The levels expression of EPHX1 had a significant association with the treatment response and prognosis of AML patients. Additionally, the EPHX1 expression levels can aid for an improved understanding of the multidrug resistant mechanism in AML.
{"title":"The Association between mrna Expression Levels of Ephx1 and Prognosis of Acute Myeloid Leukemia","authors":"Chong-mei Huang, Hui Cheng, Xiaoqian Xu, Xianmin Song, Li Chen, Jianmin Yang","doi":"10.4172/2329-6771.1000154","DOIUrl":"https://doi.org/10.4172/2329-6771.1000154","url":null,"abstract":"The human epoxide hydrolase 1 (EPHX1) is a metabolism gene, which is responsible for the first phase of the xenobiotic metabolism. The product, microsomal epoxide hydrolase (mHE), plays an important role in the detoxification of carcinogenic polycyclic aromatic hydrocarbons. Many reports also have studied the correlation between EPHX1 gene polymorphisms and development and generation of cancers. However, few of studies on EPHX1 participating in chemotherapeutics metabolism were reported. The purpose of the present study was to evaluate the prognostic significance of the EPHX1gene expression in acute myeloid leukemia (AML). Using real timeâquantitative polymerase chain reaction (RTâqPCR), mRNA expression levels of EPHX1gene was measured in bone marrow samples of newly diagnosed AML patients (n=46) and control group (n=12) without tumors. The levels expression of EPHX1 had a significant association with the treatment response and prognosis of AML patients. Additionally, the EPHX1 expression levels can aid for an improved understanding of the multidrug resistant mechanism in AML.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"232 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2015-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75854403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-11-20DOI: 10.4172/2329-6771.1000151
Ssakher M AlOtaibi, Faisal Alabbas, Nada K. Bashnini, Abdullah F. Almoshadq, Hisham M. Al-Hindi, M. Pasha, A. Alghamdi, M. Al-Ahwal, B. E. Deek
Objective: Colorectal cancer is the third most common cancer in the world. Quality of life is important to achieve successful treatment outcomes. The aim of this study was to assess the functional quality of life of patients with newly diagnosed colorectal cancer in order to improve our understanding as physicians of how cancer therapy influences the patients’ lives, and how we can help patients improve the quality of life on a daily basis. Method: This was a cross-sectional study conducted between January-September 2013, of a sample of 647 patients newly diagnosed with colon cancer at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia. Participants completed the EROTIC QLQ-CR29 questionnaire, translated into Arabic and modified for a KSA population by three oncologists. Results: In total, 40 patients were included (males, 25; females, 15). Similar findings were reported between both genders in terms of body image, postoperative complications and stomas, and these were significant issues in a substantial number of respondents. Conclusion: The quality of life of patients with colorectal cancer in KSA is poor in general, as a result of both physician- and patient-specific factors. Further studies to assess this issue are recommended. Am understanding of the difficulties that patients face should encourage physicians to consider this vital aspect of their care, positively influencing the treatment course with the aim of creating the conditions for a peaceful and optimal psychological, as well as disease, outcome.
{"title":"Functional Assessment of Quality of Life Using EORTC QLQ-CR29 inPatients with Colon Cancer at King Abdulaziz University Hospital","authors":"Ssakher M AlOtaibi, Faisal Alabbas, Nada K. Bashnini, Abdullah F. Almoshadq, Hisham M. Al-Hindi, M. Pasha, A. Alghamdi, M. Al-Ahwal, B. E. Deek","doi":"10.4172/2329-6771.1000151","DOIUrl":"https://doi.org/10.4172/2329-6771.1000151","url":null,"abstract":"Objective: Colorectal cancer is the third most common cancer in the world. Quality of life is important to achieve successful treatment outcomes. The aim of this study was to assess the functional quality of life of patients with newly diagnosed colorectal cancer in order to improve our understanding as physicians of how cancer therapy influences the patients’ lives, and how we can help patients improve the quality of life on a daily basis. Method: This was a cross-sectional study conducted between January-September 2013, of a sample of 647 patients newly diagnosed with colon cancer at the King Abdulaziz University Hospital, Jeddah, Saudi Arabia. Participants completed the EROTIC QLQ-CR29 questionnaire, translated into Arabic and modified for a KSA population by three oncologists. Results: In total, 40 patients were included (males, 25; females, 15). Similar findings were reported between both genders in terms of body image, postoperative complications and stomas, and these were significant issues in a substantial number of respondents. Conclusion: The quality of life of patients with colorectal cancer in KSA is poor in general, as a result of both physician- and patient-specific factors. Further studies to assess this issue are recommended. Am understanding of the difficulties that patients face should encourage physicians to consider this vital aspect of their care, positively influencing the treatment course with the aim of creating the conditions for a peaceful and optimal psychological, as well as disease, outcome.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2015-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81984159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-11-10DOI: 10.4172/2329-6771.1000149
Hui Chang, W. Xiao, Lu-ning Zhang, B. Qiu, Yong Chen, Jian-ming Gao, Yong Su, Lixia Lu, Yuan-hong Gao
Background: Concurrent chemo-radiation is now the standard treatment of nasopharyngeal carcinoma. However, distant metastases remain the major cause of death. The purpose of this study was to evaluate the impact of neoadjuvant chemotherapy of 3 cycles or more on survival of patients with N2-3 nasopharyngeal carcinoma. Methods: In this study, a total of 553 consecutive patients with non-metastatic N2-3 nasopharyngeal carcinoma were recruited. 102 patients with neoadjuvant chemotherapy of 3 cycles or more (NACT≥3 group) were matched 1:2:1 to 204 patients with neoadjuvant chemotherapy of 2 cycles (NACT=2 group) and 102 patients without neoadjuvant chemotherapy (NACT=0 group), according to age, N stage, histological subtype, neoadjuvant chemotherapy regimen. Five candidate variables (sex, T stage, concurrent chemotherapy, intensity-modulated radiation therapy and cycle number of neoadjuvant chemotherapy) were analyzed for association with survival. Results: After matching, 5-year overall survival, 5-year disease-free survival, 5-year local-recurrence-free survival and 5-year distant-metastasis-free survival of NACT≥3 group were better than those of NACT=2 group and those of NACT=0 group. In multivariate analysis, sex, T stage and cycle number of neoadjuvant chemotherapy maintained statistical significance on 5-year overall survival (P values were 0.029, <0.001 and <0.001), 5-year disease-free survival (P values were 0.020, <0.001 and 0.002), 5-year local-recurrence-free survival (P values were 0.048, 0.001 and 0.002) and 5-year distant-metastasis-free survival (P values were 0.017, <0.001 and <0.001). Conclusion: For N2-3 nasopharyngeal carcinoma, neoadjuvant chemotherapy of 3 cycles or more appeared to be an independent factor associated with improvement of survival.
{"title":"Neoadjuvant Chemotherapy of Three Cycles or More Improve Survival ofPatients with N2-3 Nasopharyngeal Carcinoma","authors":"Hui Chang, W. Xiao, Lu-ning Zhang, B. Qiu, Yong Chen, Jian-ming Gao, Yong Su, Lixia Lu, Yuan-hong Gao","doi":"10.4172/2329-6771.1000149","DOIUrl":"https://doi.org/10.4172/2329-6771.1000149","url":null,"abstract":"Background: Concurrent \u0000chemo-radiation \u0000is now the standard treatment of nasopharyngeal carcinoma. However, distant metastases remain the major cause of death. The purpose of this study was to evaluate the impact of neoadjuvant chemotherapy of 3 cycles or more on survival of patients with N2-3 nasopharyngeal carcinoma. Methods: In this study, a total of 553 consecutive patients with non-metastatic N2-3 nasopharyngeal carcinoma were recruited. 102 patients with neoadjuvant chemotherapy of 3 cycles or more (NACT≥3 group) were matched 1:2:1 to 204 patients with neoadjuvant chemotherapy of 2 cycles (NACT=2 group) and 102 patients without neoadjuvant chemotherapy (NACT=0 group), according to age, N stage, histological subtype, neoadjuvant chemotherapy regimen. Five candidate variables (sex, T stage, concurrent chemotherapy, \u0000intensity-modulated radiation therapy \u0000and cycle number of neoadjuvant chemotherapy) were analyzed for association with survival. Results: After matching, 5-year overall survival, 5-year disease-free survival, 5-year local-recurrence-free survival and 5-year distant-metastasis-free survival of NACT≥3 group were better than those of NACT=2 group and those of NACT=0 group. In multivariate analysis, sex, T stage and cycle number of neoadjuvant chemotherapy maintained statistical significance on 5-year overall survival (P values were 0.029, <0.001 and <0.001), 5-year disease-free survival (P values were 0.020, <0.001 and 0.002), 5-year local-recurrence-free survival (P values were 0.048, 0.001 and 0.002) and 5-year distant-metastasis-free survival (P values were 0.017, <0.001 and <0.001). Conclusion: For N2-3 nasopharyngeal carcinoma, neoadjuvant chemotherapy of 3 cycles or more appeared to be an independent factor associated with improvement of survival.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"23 1","pages":"1-7"},"PeriodicalIF":0.0,"publicationDate":"2015-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86672224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-10-15DOI: 10.4172/2329-6771.1000148
Luís Pinho, F. Mendes, M. M. Rodrigues, Jéssica Estrela, R. Teixo, R. Cruz
Lung cancer presents a heterogeneous nature, which became more and more evident. Generally this type of cancer in an advanced state has a poor prognosis. The discovery of multiple molecular mechanisms, associated to the development, proliferation and prognosis of lung cancer has created new opportunities for a targeted therapy, improving clinical results. Non-small cells lung cancer is characterized by mutations on Epidermal Growth Factor Receptor and/or in the signaling pathways related to this receptor, which promoted the development of selective monoclonal antibodies and Epidermal Growth Factor Receptor-Tirosine Kinase Inhibitors, blocking the proliferation, differentiation, angiogenesis and tumor survival. Thus, our review highlighted the importance of a continuous research of new molecular targets in lung cancer to achieve better therapeutic outcomes and overall survival rates.
{"title":"Molecular Targets in Lung Cancer Therapy: A Current Review","authors":"Luís Pinho, F. Mendes, M. M. Rodrigues, Jéssica Estrela, R. Teixo, R. Cruz","doi":"10.4172/2329-6771.1000148","DOIUrl":"https://doi.org/10.4172/2329-6771.1000148","url":null,"abstract":"Lung cancer presents a heterogeneous nature, which became more and more evident. Generally this type of cancer in an advanced state has a poor prognosis. The discovery of multiple molecular mechanisms, associated to the development, proliferation and prognosis of lung cancer has created new opportunities for a targeted therapy, improving clinical results. Non-small cells lung cancer is characterized by mutations on Epidermal Growth Factor Receptor and/or in the signaling pathways related to this receptor, which promoted the development of selective monoclonal antibodies and Epidermal Growth Factor Receptor-Tirosine Kinase Inhibitors, blocking the proliferation, differentiation, angiogenesis and tumor survival. Thus, our review highlighted the importance of a continuous research of new molecular targets in lung cancer to achieve better therapeutic outcomes and overall survival rates.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"62 2-3","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2015-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91522754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-30DOI: 10.4172/2329-6771.1000147
F. He, Yan Ma, Jian Zheng, X. Pang, Qun Zhang, Wei Luo, X. Wan
Purpose: Nasopharyngeal carcinoma (NPC) has the worldwide highest incidence in Southern China. Here, we investigate the efficacy and safety of induction chemotherapy of docetaxel, cisplatin, and 5-fluorouracil (TPF) plus concurrent cisplatin based intensity-modulated radiotherapy (IMRT) in locoregionally advanced NPC. Materials and Methods: From October 2009 to August 2012, 76 NPC patients treated by TFP induction chemotherapy plus concurrent cisplatin-IMRT were retrospectively recruited. The survival rate, accurate and late toxicities were further analyzed with 3 year follow-up. Results: The median follow-up time was 42 months (range, 8 to 60 months). The 3- year disease free survival (DFS), overall survival (OS), Local relapse free survival (LRFS), Distant metastasis free survival (DMFS) was 86.6%, 94.5%, 94.7%, and 89.2%, respectively. The major acute toxicities were myelosuppression, gastrointestinal disorders, and mucositis. The major late toxicities were skin reaction, xerostomia and hearing loss. Multivariate analyses indicated that lymph node metastasis status (N stage) was independent prognostic factor for DFS (P = 0.044, hazard ratio 4.832) and DMFS (P = 0.036, hazard ratio 7.309). Conclusions: TPF induction chemotherapy plus concurrent cisplatin-IMRT achieved satisfying 3-year survival rates with acceptable toxicities, suggesting that this combined therapeutic regimen might be effective for locoregionally advanced NPC.
{"title":"Effects of Induction Chemotherapy of Docetaxel, Cisplatin, and5-Fluorouracil Combining Intensity-Modulated Radiotherapy andConcurrent Chemotherapy in Locoregionally Advanced NasopharyngealCarcinoma","authors":"F. He, Yan Ma, Jian Zheng, X. Pang, Qun Zhang, Wei Luo, X. Wan","doi":"10.4172/2329-6771.1000147","DOIUrl":"https://doi.org/10.4172/2329-6771.1000147","url":null,"abstract":"Purpose: Nasopharyngeal carcinoma (NPC) has the worldwide highest incidence in Southern China. Here, we investigate the efficacy and safety of induction chemotherapy of docetaxel, cisplatin, and 5-fluorouracil (TPF) plus concurrent cisplatin based intensity-modulated radiotherapy (IMRT) in locoregionally advanced NPC. \u0000Materials and Methods: From October 2009 to August 2012, 76 NPC patients treated by TFP induction chemotherapy plus concurrent cisplatin-IMRT were retrospectively recruited. The survival rate, accurate and late toxicities were further analyzed with 3 year follow-up. \u0000Results: The median follow-up time was 42 months (range, 8 to 60 months). The 3- year disease free survival (DFS), overall survival (OS), Local relapse free survival (LRFS), Distant metastasis free survival (DMFS) was 86.6%, 94.5%, 94.7%, and 89.2%, respectively. The major acute toxicities were myelosuppression, gastrointestinal disorders, and mucositis. The major late toxicities were skin reaction, xerostomia and hearing loss. Multivariate analyses indicated that lymph node metastasis status (N stage) was independent prognostic factor for DFS (P = 0.044, hazard ratio 4.832) and DMFS (P = 0.036, hazard ratio 7.309). \u0000Conclusions: TPF induction chemotherapy plus concurrent cisplatin-IMRT achieved satisfying 3-year survival rates with acceptable toxicities, suggesting that this combined therapeutic regimen might be effective for locoregionally advanced NPC.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"2 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2015-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75176877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：